Mobile

Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma (NHL): a phase III randomised clinical trial (Intergrou...

Mise à jour : Il y a 4 ans
Référence : ISRCTN65655917

Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma (NHL): a phase III randomised clinical trial (Intergroup Collaborative Study)

Femme et Homme

Extrait

Not provided at time of registration

Critère d'inclusion

  • Lymphoma (non-Hodgkin's)

Liens